Endovascular Engineering, Inc. Announces Positive Initial Results in ENGULF Study for Hēlo™ Thrombectomy System

ENGULF Study utilizing next generation technology in targeting pulmonary embolism MENLO PARK, Calif., Oct. 31, 2023 /PRNewswire/ — Endovascular Engineering (“E2”), a mission driven, venture-backed, medical device company focused on the development and deployment of next generation clot…

Click here to view original post